Komodo Health & Intercept Partner to Study Rare Liver Disease

💡 This post was automatically imported from HIT Consultant. You can find the original article here.
Author: HIT Consultant Media (Jasmine Pennic)

Komodo Health

What You Should Know:

Komodo Health announced its collaboration with Intercept Pharmaceuticals to power clinical research and new real-world evidence (RWE) with Komodo’s platform. 

Leveraging Komodo’s tech platform and Healthcare Map, Intercept was able to conduct a retrospective real-world study on the long term outcomes for Ocaliva — a therapeutic for rare liver disease, primary biliary cholangitis (PBC). 

Partnership Details

Intercept initially developed a traditional prospective trial to evaluate patients with advanced PBC using Ocaliva, but terminated it due to feasibility challenges in this rare disease that impacts less than 1% of women (65 in 100,000). To fill this evidence gap, Intercept turned to Komodo. Using Komodo’s Healthcare Map, Intercept was able to look at outcomes in a pre-defined group of patients with PBC who were treated with Ocaliva to see how they differ from a comparable group of PBC patients who were eligible, but who were not treated with Ocaliva.

With insights on how more than 330 million U.S. patients interact with the healthcare system, Komodo’s Healthcare Map provides an accessible, actionable, and scalable approach to studying rare disease. With Komodo, Intercept researchers were able to determine that patients receiving Ocaliva improved significantly.

The News Aggregator will pull the latest articles and news from around the internet to present them in one place for you to easily keep up to date on all things related to Medical Informatics.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

Welcome to MediFormatica. The site is still under construction so there are some rough edges here and there, but I'll be adding new and exciting content every day. So enjoy it and come back again for more great stuff.